Where: Bldg 9, Lecture Hall 2325
Description
NMR-based Metabolomics offer great promise in helping us diagnose disease early and create treatments that suit indiviuals. This lecture will describe several examples in which metabolomics and biomarker analysis are being used for novel drug characterization and disease prognostics and diagnostics. Metabolomics is the study of global metabolite profiles in a biological system, joining genomics, transcriptomics and proteomics to facilitate a comprehensive understanding of a biological system. Metabolites are the end products of gene expression. The metabolome can be defined as the complete set of small-molecule metabolites (such as metabolic intermediates, hormones and other signaling molecules, as well as secondary metabolites) to be found in a biological sample. Since most physiologically relevant metabolites are ultimately filtered, urine is a useful fluid that provides a snapshot of the metabolome. Attendees of this lecture will be provided with basic information and tools that will allow them to apply metabolomics in their own research projects, possibly in conjunction with the NMR core lab at KAUST, which is equipped with state-of-the-art instrumentation in metabolomics.
Abdul-Hamid Emwas
Abdul-Hamid Emwas, is a staff scientist at Imaging and Characterization Core Lab, KAUST. Dr. Emwas received a Ph.D. in Physical Chemistry from the University of New Brunswick, Canada, and his M.Sc. in Biophysical Chemistry, from the University of Bergen, Bergen, Norway. He graduated earlier with B.Sc. (Chemistry), from the University of Bir-Zeit, Bir-Zeit, Palestine. His research interest is in developing new NMR and EPR approaches for protein and DNA structural analysis. Currently, Dr. Emwas’ research focus is on developing, optimizing and standardizing novel NMR metabolomics approaches that can be used as a diagnostic and prognostic tool for human diseases.
Tony William Antakly
Tony Antakly is a tenured Professor of Biochemistry and Molecular Medicine at the University of Montreal. He holds two doctorates in cell and molecular biology from the University of Paris including a D.Sc. (Doctorat ès-sciences d’État) obtained in 1983. He completed post-doctoral training at Laval University, Columbia University of New York and the NIH in Bethesda. Author of more than 100 scientific publications and communications, his main research interests relate to molecular mechanisms of hormone action, the expression of specific cellular genes during the tumoral process and development of novel pharmaceutical products. Over the years, his laboratory has received funding from peer-reviewed agencies including the C.I.H.R. Canada, the US National Institutes of Health, Canadian Foundation for AIDS Research, the National Health and Research Development Program of the Canadian Health Ministry (Health-Canada) and the National Cancer Institute of Canada. The Biologic and Genetic Therapies Directorate of Health Canada (FDA homologue) granted him approval to test on humans a molecule discovered by his group. In late 1990`s, T. Antakly founded two University spin-off Biotech ventures. He directed the R&D studies on a novel therapeutic metabolite up to Phase II clinical trials. He also participated in University-Industry development initiatives and acted as member of several academic intellectual property committees including one that oversees the corporation responsible for University of Montreal technology valorization.
No resources found.
No links found.
